These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 15229493)

  • 1. Courts crack down on drug marketing strategies.
    Ready T
    Nat Med; 2004 Jul; 10(7):655. PubMed ID: 15229493
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug marketing exclusivity under United States and European Union law.
    Junod V
    Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347
    [No Abstract]   [Full Text] [Related]  

  • 3. Major medical journals will require registration of clinical trials for publication.
    Levenson D
    Rep Med Guidel Outcomes Res; 2004 Oct; 15(19):1-2, 6-7. PubMed ID: 15473047
    [No Abstract]   [Full Text] [Related]  

  • 4. Mandatory post marketing studies.
    Somberg J
    Am J Ther; 2007; 14(4):321. PubMed ID: 17667203
    [No Abstract]   [Full Text] [Related]  

  • 5. Big Pharma's Commedia.
    Steele FR
    Cell; 2005 Dec; 123(6):971-3. PubMed ID: 16360023
    [No Abstract]   [Full Text] [Related]  

  • 6. Journal grows suspicious of Vioxx data.
    Wadman M
    Nature; 2005 Dec; 438(7070):899. PubMed ID: 16355178
    [No Abstract]   [Full Text] [Related]  

  • 7. The ODAC Chronicles: Part 3. The FDA's philosophy and process for cancer drug evaluation and approval.
    Grillo-López AJ
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):1-5. PubMed ID: 15757431
    [No Abstract]   [Full Text] [Related]  

  • 8. Sending pharma better signals.
    Avorn J
    Science; 2005 Jul; 309(5735):669. PubMed ID: 16051753
    [No Abstract]   [Full Text] [Related]  

  • 9. Avoiding legal and ethical pitfalls of industry-sponsored research: the co-existence of research, scholarship, and marketing in the pharmaceutical industry.
    Dorfman HL; Reig LP
    Food Drug Law J; 2004; 59(4):595-615. PubMed ID: 15880876
    [No Abstract]   [Full Text] [Related]  

  • 10. The importance of the state medical journal to the pharmaceutical industry.
    Stetler CJ
    J Med Assoc Ga; 1968 Feb; 57(2):73-7. PubMed ID: 5639734
    [No Abstract]   [Full Text] [Related]  

  • 11. New clinical trials policy at FDA.
    Vastag B
    Nat Biotechnol; 2006 Sep; 24(9):1043. PubMed ID: 16964196
    [No Abstract]   [Full Text] [Related]  

  • 12. The Food and Drug Administration perspective: use of an investigational drug in a medical emergency.
    Schultheis LW; Rappaport BA
    Anesth Analg; 2007 Mar; 104(3):479-80. PubMed ID: 17312189
    [No Abstract]   [Full Text] [Related]  

  • 13. The professional society circus.
    Kassirer JP
    J Public Health Policy; 2005 Dec; 26(4):400-3. PubMed ID: 16392739
    [No Abstract]   [Full Text] [Related]  

  • 14. Trials and error.
    Jacobs T
    Nat Biotechnol; 2005 Dec; 23(12):1481. PubMed ID: 16333284
    [No Abstract]   [Full Text] [Related]  

  • 15. Overhauling clinical trials.
    Scott CT; Baker M
    Nat Biotechnol; 2007 Mar; 25(3):287-92. PubMed ID: 17344876
    [No Abstract]   [Full Text] [Related]  

  • 16. The special treatment.
    Osborne R
    Nat Biotechnol; 2008 May; 26(5):487-9. PubMed ID: 18464770
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug companies, doctors and disclosures.
    Tuorto S; Chan MK; Adusumilli PS
    Natl Med J India; 2004; 17(4):215-6. PubMed ID: 15372772
    [No Abstract]   [Full Text] [Related]  

  • 18. Drive for drugs leads to baby clinical trials.
    Nature; 2006 Mar; 440(7083):406-7. PubMed ID: 16554774
    [No Abstract]   [Full Text] [Related]  

  • 19. Orphan products: definition and activities.
    Finkel MJ
    Prog Clin Biol Res; 1983; 127():159-71. PubMed ID: 6351098
    [No Abstract]   [Full Text] [Related]  

  • 20. Withdrawal syndrome.
    Nat Med; 2004 Nov; 10(11):1143. PubMed ID: 15516887
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.